This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
Drug: lapatinib + capecitabine
Experimental
Inclusion criteria:
- May have received prior lapatinib in another trial. Previous capecitabine (as previous agent or non-lapatinib containing regimen) is also permitted.
- Prior treatment with hormonal therapy is allowed.
- Must have advanced or metastatic breast cancer with progression (as assessed by modified RECIST) after prior therapy, which must include all of the following: prior treatment with an anthracycline, a taxane, and trastuzumab alone or in combination with other therapy. Trastuzumab must have been administered in the adjuvant, or locally advanced or metastatic setting.
- Must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive for ErbB2 gene amplification. The status of ErbB2 expression must be documented prior to study entry.
- Must be >/= 18 years of age
- Life expectancy of > 8 weeks
- Must have recovered from side effects of previous treatment
- Patients with CNS mets are eligible provided treatment with prohibited medications as listed in the protocol are not required
- Cardiac ejection fraction must be within the institutional range of normal as measured by ECHO. MUGA scans are allowed if ECHOs cannot be performed
- Able to swallow and retain oral medications
- Must have adequate hematologic, hepatic and renal function
Exclusion criteria:
- Pregnant or lactating females
- Malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or bowel, or ulcerative colitis
- Concurrent disease or condition that would make the patient inappropriate for study participation
- Unresolved or unstable toxicity from prior administration of another investigational drug and/or prior cancer treatment
- Uncontrolled infection
- Active cardiac disease defined as history of uncontrolled or symptomatic angina; history of arrhythmias requiring medication, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation; MI < 6 months from study entry; uncontrolled or symptomatic CHF; ejection fraction below the institutional normal limit; any other cardiac condition that would make this protocol unreasonably hazardous for the patient
- Receiving concurrent chemotherapy (other than capecitabine), radiation therapy, immunotherapy, biologic therapy or hormonal therapy for cancer. Concurrent therapy with bisphosphonates is allowed
- History of allergic reaction attributed to compounds of similar composition to lapatinib or any excipients
- History of allergic reactions attributed to compounds of similar chemical composition to capecitabine, fluorouracil or excipients
- Known DPD deficiency
Novartis Investigative Site
Huntsville, Alabama, 35805
Novartis Investigative Site
Anchorage, Alaska, 99508
Novartis Investigative Site
Glendale, Arizona, 85304
Novartis Investigative Site
Fayetteville, Arkansas, 72703
Novartis Investigative Site
Little Rock, Arkansas, 72205
Novartis Investigative Site
Bellflower, California, 90706
Novartis Investigative Site
Burbank, California, 91505-4866
Novartis Investigative Site
Gilroy, California, 95020
Novartis Investigative Site
Long Beach, California, 90806
Novartis Investigative Site
Long Beach, California, 90813
Novartis Investigative Site
Newport Beach, California, 92663
Novartis Investigative Site
San Diego, California, 92123
Novartis Investigative Site
San Francisco, California, 94115-1710
Novartis Investigative Site
Santa Rosa, California, 95403-1757
Novartis Investigative Site
Stockton, California, 95204
Novartis Investigative Site
Aurora, Colorado, 80010
Novartis Investigative Site
Boulder, Colorado, 80304
Novartis Investigative Site
Lafayette, Colorado, 80026
Novartis Investigative Site
Hartford, Connecticut, 06105
Novartis Investigative Site
Manchester, Connecticut, 06040
Novartis Investigative Site
New Havey, Connecticut, 06511
Novartis Investigative Site
Norwich, Connecticut, 06360
Novartis Investigative Site
Washington, District of Columbia, 20007
Novartis Investigative Site
Fort Lauderdale, Florida, 33328
Novartis Investigative Site
Fort Myers, Florida, 33916
Novartis Investigative Site
Fort Walton Beach, Florida, 32547
Novartis Investigative Site
Gainesville, Florida, 32605
Novartis Investigative Site
Hollywood, Florida, 33021
Novartis Investigative Site
Jacksonville, Florida, 32256
Novartis Investigative Site
Miami, Florida, 33133
Novartis Investigative Site
Orlando, Florida, 32804
Novartis Investigative Site
Orlando, Florida, 32806
Novartis Investigative Site
Tampa, Florida, 33607
Novartis Investigative Site
Augusta, Georgia, 30901
Novartis Investigative Site
Brunswick, Georgia, 31525
Novartis Investigative Site
Macon, Georgia, 31201
Novartis Investigative Site
Marietta, Georgia, 30060
Novartis Investigative Site
Tucker, Georgia, 30084
Novartis Investigative Site
Honolulu, Hawaii, 96813
Novartis Investigative Site
Boise, Idaho, 83712
Novartis Investigative Site
Chicago, Illinois, 60637
Novartis Investigative Site
Decatur, Illinois, 62526
Novartis Investigative Site
Galesburg, Illinois, 61401
Novartis Investigative Site
Highland Park, Illinois, 60035
Novartis Investigative Site
Joliet, Illinois, 60435
Novartis Investigative Site
Peoria, Illinois, 61615
Novartis Investigative Site
Zion, Illinois, 60099
Novartis Investigative Site
Indianapolis, Indiana, 46202
Novartis Investigative Site
Bettendorf, Iowa, 52722
Novartis Investigative Site
Cedar Rapids, Iowa, 52403
Novartis Investigative Site
Council Bluffs, Iowa, 51503
Novartis Investigative Site
Sioux City, Iowa, 51101-1733
Novartis Investigative Site
Waterloo, Iowa, 50702
Novartis Investigative Site
Baton Rouge, Louisiana, 70809
Novartis Investigative Site
Metairie, Louisiana, 70006
Novartis Investigative Site
Portland, Maine, 04101
Novartis Investigative Site
Scarborough, Maine, 04074
Novartis Investigative Site
Waterville, Maine, 04901
Novartis Investigative Site
Baltimore, Maryland, 21231-1000
Novartis Investigative Site
Baltimore, Maryland, 21237
Novartis Investigative Site
Chevy Chase, Maryland, 20815
Novartis Investigative Site
Frederick, Maryland, 21701
Novartis Investigative Site
Boston, Massachusetts, 02111
Novartis Investigative Site
Boston, Massachusetts, 02118
Novartis Investigative Site
Fall River, Massachusetts, 02721
Novartis Investigative Site
Peabody, Massachusetts, 01960
Novartis Investigative Site
Ann Arbor, Michigan, 48106
Novartis Investigative Site
Detroit, Michigan, 48202
Novartis Investigative Site
Royal Oak, Michigan, 48073
Novartis Investigative Site
Troy, Michigan, 48085
Novartis Investigative Site
Duluth, Minnesota, 55802
Novartis Investigative Site
Jackson, Mississippi, 39202
Novartis Investigative Site
Columbia, Missouri, 65201
Novartis Investigative Site
Kalamazoo, Missouri, 49007
Novartis Investigative Site
Kansas City, Missouri, 64118
Novartis Investigative Site
Springfield, Missouri, 65807
Novartis Investigative Site
St. Louis, Missouri, 63110
Novartis Investigative Site
St. Louis, Missouri, 63141
Novartis Investigative Site
Billings, Montana, 59101
Novartis Investigative Site
Great Falls, Montana, 59405
Novartis Investigative Site
Grand Island, Nebraska, 68803
Novartis Investigative Site
Lincoln, Nebraska, 68510
Novartis Investigative Site
North Platte, Nebraska, 69103
Novartis Investigative Site
Omaha, Nebraska, 68114
Novartis Investigative Site
Omaha, Nebraska, 68124-2346
Novartis Investigative Site
Las Vegas, Nevada, 89102
Novartis Investigative Site
Exeter, New Hampshire, 03833
Novartis Investigative Site
Flemington, New Jersey, 08822
Novartis Investigative Site
Freehold, New Jersey, 07728
Novartis Investigative Site
Little Silver, New Jersey, 07739
Novartis Investigative Site
Livingston, New Jersey, 07039
Novartis Investigative Site
Mountain Lakes, New Jersey, 07046
Novartis Investigative Site
Newark, New Jersey, 07112
Novartis Investigative Site
Buffalo, New York, 14221
Novartis Investigative Site
Buffalo, New York, 14263
Novartis Investigative Site
East Setauket, New York, 11733
Novartis Investigative Site
East Syracuse, New York, 13057
Novartis Investigative Site
Fresh Meadows, New York, 11366
Novartis Investigative Site
Glens Falls, New York, 12801
Novartis Investigative Site
New York, New York, 10003
Novartis Investigative Site
New York, New York, 10011
Novartis Investigative Site
New York, New York, 10016
Novartis Investigative Site
New York, New York, 10065
Novartis Investigative Site
Asheville, North Carolina, 28816
Novartis Investigative Site
Charlotte, North Carolina, 28203
Novartis Investigative Site
Charlotte, North Carolina, 28204
Novartis Investigative Site
Fayetteville, North Carolina, 28304
Novartis Investigative Site
Greensboro, North Carolina, 27403
Novartis Investigative Site
Bismarck, North Dakota, 58501
Novartis Investigative Site
Fargo, North Dakota, 58122
Novartis Investigative Site
Cincinnati, Ohio, 45219
Novartis Investigative Site
Cincinnati, Ohio, 45242
Novartis Investigative Site
Cleveland, Ohio, 44106
Novartis Investigative Site
Columbus, Ohio, 39705
Novartis Investigative Site
Columbus, Ohio, 43210
Novartis Investigative Site
Sandusky, Ohio, 44870
Novartis Investigative Site
Oklahoma City, Oklahoma, 73109
Novartis Investigative Site
Tulsa, Oklahoma, 74104
Novartis Investigative Site
Tulsa, Oklahoma, 74133
Novartis Investigative Site
Klamath Falls, Oregon, 97601
Novartis Investigative Site
Portland, Oregon, 97213
Novartis Investigative Site
Drexel Hill, Pennsylvania, 19026
Novartis Investigative Site
Philadelphia, Pennsylvania, 19104
Novartis Investigative Site
Philadelphia, Pennsylvania, 19106
Novartis Investigative Site
Philadelphia, Pennsylvania, 19111
Novartis Investigative Site
Pittsburgh, Pennsylvania, 15212-4772
Novartis Investigative Site
Pittsburgh, Pennsylvania, 15213
Novartis Investigative Site
Pottstown, Pennsylvania, 19464
Novartis Investigative Site
Sayre, Pennsylvania, 18840
Novartis Investigative Site
State College, Pennsylvania, 16803
Novartis Investigative Site
Charleston, South Carolina, 29403
Novartis Investigative Site
Columbia, South Carolina, 29210
Novartis Investigative Site
Florence, South Carolina, 29506
Novartis Investigative Site
Mt. Pleasant, South Carolina, 29464
Novartis Investigative Site
Knoxville, Tennessee, 37916
Novartis Investigative Site
Memphis, Tennessee, 38120
Novartis Investigative Site
Nashville, Tennessee, 37203
Novartis Investigative Site
Arlington, Texas, 76012
Novartis Investigative Site
Austin, Texas, 78731
Novartis Investigative Site
Austin, Texas, 78759
Novartis Investigative Site
Dallas, Texas, 75230
Novartis Investigative Site
Dallas, Texas, 75246
Novartis Investigative Site
El Paso, Texas, 79912
Novartis Investigative Site
Houston, Texas, 77030
Novartis Investigative Site
Houston, Texas, 77230-1439
Novartis Investigative Site
San Antonio, Texas, 78207
Novartis Investigative Site
Salt Lake City, Utah, 84112-5550
Novartis Investigative Site
Fairfax, Virginia, 22031
Novartis Investigative Site
Richmond, Virginia, 23230
Novartis Investigative Site
Richmond, Virginia, 23294
Novartis Investigative Site
Kennewick, Washington, 99336
Novartis Investigative Site
Mount Vernon, Washington, 98273
Novartis Investigative Site
Seattle, Washington, 98112
Novartis Investigative Site
Tacoma, Washington, 98405
Novartis Investigative Site
Walla Walla, Washington, 99362
Novartis Investigative Site
Morgantown, West Virginia, 26506
Novartis Investigative Site
Green Bay, Wisconsin, 54311
Novartis Investigative Site
La Crosse, Wisconsin, 54601
Novartis Investigative Site
Marshfield, Wisconsin, 54449
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals